 randomized trial intravenous oral etoposide combination cisplatin treatment small cell lung cancer randomized multi-center study patients small cell lung cancer treatment cisplatin IV day IV days IV day IV day days regimens weeks Prior randomization patients extent disease performance status gender total patients parenteral treatment regimen patients cisplatin IV/oral therapy treatment arms comparable patient characteristics Limited disease LD patients patient population oral IV overall complete response CR partial response PR rate confidence interval CI oral etoposide regimen CI IV etoposide regimen regimens LD patients CR PR Time progression survival comparable treatment arms Hematologic toxicity comparable treatment arms patients grade neutropenia thrombocytopenia Moderate anemia weight loss predominant IV oral regimen